Mometasone Furoate Use for Recurrent Adenoid Hypertrophy: Randomized Controlled Clinical Trial

Abstract

Background& Objective: Adenoid hypertrophy (AH) in children is one of the most causes of nasal obstruction and is associated with many nasal and respiratory symptoms. Till now, surgery is the main option for managing the associated symptom of AH. The intranasal steroid has an effective role in the control of allergic rhinitis and associated AH. This work aimed to assess the effects of local mometasone on recurrent AH in children. Patients& Methods: A randomized controlled trial enrolled 39 patients aged between 2 and 15 years with recurrent AH. Those patients were randomly subdivided into three groups; group (A) received topical mometasone furoate (MF), group (B) did not receive any medication, and group (C) received topical normal saline. All groups were followed up for 8 weeks. Results: Patients who received Mometasone furoate had temporary relief of adenoid hypertrophy-related symptoms (84.6%) in comparison to the control group and placebo group during the duration of treatment. After cessation of treatment with local steroids, all cases experienced symptoms caused by adenoid hypertrophy, and by the end of the third month of follow up all cases underwent adenoidectomy. Conclusion: Mometasone furoate can temporarily reduce the adenoid size, reducing symptoms related to adenoid hypertrophy.

Keywords: Adenoid hypertrophy; Hypo-nasal speech; Mometasone furoate; Naso-endoscopy.

Fig. 1

Follow up of 8 years male patient in the MF group X-ray lateral view of nasopharynx shows adenoids reduction (pretreatment 1a and posttreatment 1a). Endoscopic evaluation of adenoids size (pretreatment 2a and post-treatment 2b).

Fig. 2

Flow chart of the current study summarizing pathways of all children enrolled in our study and showing temporary improvement of symptoms related to adenoid hypertrophy in patients in group A with no improvement in both groups B and C